Hepion 10-Q: $4.3M Cash, Going Concern Doubt, and Material Weaknesses Disclosed
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion's Q3 2026 10-Q shows $4.3 million of cash, a going-concern warning, and newly disclosed material weaknesses in internal controls; the $4.58 million quarterly loss is mostly a non-cash warrant remeasurement.
Key Events · Earnings and Guidance · CTRVP
-
Going Concern Doubt Reiterated
Management concluded there is substantial doubt about Hepion's ability to continue as a going concern within one year without additional capital, with $4.3 million of cash against a $252.7 million accumulated deficit and a $4.0 million stockholders' deficit.
-
Q3 Loss Mostly Non-Cash Warrant Mark
Net loss was $4.58 million for the quarter, including a $3.04 million non-cash change in fair value of warrant liabilities driven by the higher stock price; nine-month operating cash burn was $1.7 million.
-
Material Weaknesses Disclosed
Disclosure controls were not effective at September 30, 2026 due to material weaknesses in segregation of duties, review of complex accounting transactions and the income tax provision; remediation steps are underway but not yet tested.
-
Warrant Liability Swells to $7.9M
68,698,111 warrants from the July and August 2026 offerings were liability-classified because authorized shares were insufficient, carrying $7.87 million of fair value at September 30, 2026 versus $0.10 million at December 31, 2025.
Analysis · CTRVP · Life Sciences
Hepion ended Q3 2026 with $4.3 million in cash against a $252.7 million accumulated deficit and a $4.0 million stockholders' deficit, and management states there is substantial doubt about the company's ability to continue as a going concern within one year without new capital. Most of the $4.58 million quarterly net loss is accounting noise: $3.04 million of it is a non-cash mark-to-market change in warrant liability driven by the higher share price, not a cash outflow and not new dilution. Real cash burn was $1.7 million over nine months. The filing also discloses for the first time that disclosure controls were not effective because of material weaknesses tied to thin staffing, complex-transaction review and the tax provision. The company is now a diagnostics/clinical-stage story built on the October 6 GLS acquisition, funded by repeated $0.04-$0.05 private placements that have taken shares outstanding from 11.6 million to 100.1 million during 2026.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.